Who
Onaiza Cadoret-Manier
Director
Company insider
Files Form 4 as: Director, Ardelyx; Director, Ventyx Biosciences; EVP,Chf GL Pdt Str & Oper Ofc, Ionis Pharmaceuticals.
In numbers
- Trades disclosed
- 69
- Buys
- 0
- Sells
- 6
- Bought
- $0
- Sold
- $795K
- Companies
- 3
- Companies where not an officer
- 2
- First trade
- 9 Jan 2020
- Last trade
- 16 Jun 2026
- Last filed
- 18 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 16 Jun 2026filed 18 Jun 2026 | ARDX ArdelyxBiotechnology | SEC FORM 4 Code A | —26,455 at $0.00 | filing |
| 16 Jun 2026filed 18 Jun 2026 | ARDX Ardelyxoption or derivative · Biotechnology | SEC FORM 4 Code A | —39,715 at $0.00 | filing |
| 16 Jun 2026filed 18 Jun 2026 | ARDX Ardelyxoption or derivative · Biotechnology | SEC FORM 4 Code A | —39,715 at $0.00 | filing |
| 16 Jun 2026filed 18 Jun 2026 | ARDX ArdelyxBiotechnology | SEC FORM 4 Code A | —26,455 at $0.00 | filing |
| 4 Mar 2026filed 4 Mar 2026 | Ventyx Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code D | —33,000 | filing |
| 4 Mar 2026filed 4 Mar 2026 | Ventyx Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code D | —40,000 | filing |
| 4 Mar 2026filed 4 Mar 2026 | Ventyx Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code D | —20,000 | filing |
| 4 Mar 2026filed 4 Mar 2026 | Ventyx Biosciencesoption or derivative | SEC FORM 4 Code D | —33,000 | filing |
| 4 Mar 2026filed 4 Mar 2026 | Ventyx Biosciencesoption or derivative | SEC FORM 4 Code D | —40,000 | filing |
| 4 Mar 2026filed 4 Mar 2026 | Ventyx Biosciencesoption or derivative | SEC FORM 4 Code D | —20,000 | filing |
| 4 Mar 2026filed 4 Mar 2026 | Ventyx Biosciencesoption or derivative | SEC FORM 4 Code D | —15,937 | filing |
| 4 Mar 2026filed 4 Mar 2026 | Ventyx Biosciencesoption or derivative | SEC FORM 4 Code D | —20,427 | filing |
| 4 Mar 2026filed 4 Mar 2026 | Ventyx Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code D | —15,937 | filing |
| 4 Mar 2026filed 4 Mar 2026 | Ventyx Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code D | —20,427 | filing |
| 18 Jun 2025filed 23 Jun 2025 | ARDX Ardelyxoption or derivative · Biotechnology | SEC FORM 4 Code A | —54,059 at $0.00 | filing |
| 18 Jun 2025filed 23 Jun 2025 | ARDX ArdelyxBiotechnology | SEC FORM 4 Code A | —41,551 at $0.00 | filing |
| 5 Jun 2025filed 6 Jun 2025 | Ventyx Biosciencesoption or derivative | SEC FORM 4 Code A | —40,000 at $0.00 | filing |
| 14 Jun 2024filed 17 Jun 2024 | ARDX Ardelyxoption or derivative · Biotechnology | SEC FORM 4 Code A | —40,243 at $0.00 | filing |
| 6 Jun 2024filed 7 Jun 2024 | Ventyx Biosciencesoption or derivative | SEC FORM 4 Code A | —33,000 at $0.00 | filing |
| 2 Feb 2024filed 4 Sep 2024 | IONS Ionis PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $107K2,162 at $49.60 | filing |
News
Ionis Pharmaceuticals (NASDAQ:IONS) EVP Sells 1,357 Shares of StockIONS · dailypolitical.com · 20 Oct 2026Ionis Pharmaceuticals, Inc.: TRYNGOLZA (olezarsen) recommended for approval in the EU by CHMP for severe hypertriglyceridemia (sHTG)IONS · finanznachrichten.de · 16 Oct 2026Ionis Pharmaceuticals (NASDAQ:IONS) & Upstream Bio (NASDAQ:UPB) Head to Head ReviewIONS · dailypolitical.com · 13 Oct 2026
0 headlines in the last 90 days name Onaiza Cadoret-Manier; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.